IVVD Invivyd, Inc.
USHealthcareAs of 2026-07-10 16:00
Why IVVD matters now
Invivyd, Inc. (IVVD) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.78 with -2.53% on the session and $230.8M in market capitalization; recent performance reads 1-month -6.74% and YTD -60.73%.
The latest financial table shown here is Q1 2026, with revenue of $13.7M, net income of $-41.4M, and EPS of $-0.13. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -61.7%.
The latest indexable market news headline is "Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $9.50; recent insider activity includes Berry Tamsin filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.48
P/S
2.30
EV/EBITDA
0.62
DCF Value
$12.18
FCF Yield
-61.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.0%
Operating Margin
-146.4%
Net Margin
-138.9%
ROE
-53.5%
ROA
-32.1%
ROIC
-38.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $13.7M | $-41.4M | $-0.13 |
| Q4 2025 | $17.2M | $-11.1M | $-0.06 |
| FY 2025 | $53.4M | $-52.5M | $-0.30 |
| Q3 2025 | $13.1M | $-10.5M | $-0.06 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$9.50
Target (Median)
$9.50
Target Range
$9.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.63
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.